Follow us on:

Linkedin Facebook

GlaxoSmithKline plc 29.2% Potential Upside Indicated by Societe Generale

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

GlaxoSmithKline plc using EPIC/TICKER code (LON:GSK) has had its stock rating noted as ‘Retains’ with the recommendation being set at ‘BUY’ this morning by analysts at Societe Generale. GlaxoSmithKline plc are listed in the Health Care sector within UK Main Market. Societe Generale have set their target price at 2300 GBX on its stock. This is indicating the analyst believes there is a potential upside of 29.2% from the opening price of 1780 GBX. Over the last 30 and 90 trading days the company share price has increased 29.8 points and increased 83.8 points respectively. The 52 week high for the stock is 1850.4 GBX while the year low stock price is currently 1429.8 GBX.

GlaxoSmithKline plc has a 50 day moving average of 1,762.20 GBX and the 200 Day Moving Average price is recorded at 1,672.02. There are currently 4,989,596,281 shares in issue with the average daily volume traded being 8,609,049. Market capitalisation for LON:GSK is £89,303,796,673 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

    Latest Company News

    Broker Ratings

    GSK plc 22.3% potential upside indicated by Berenberg Bank

    GSK Plc

    GSK Plc FIRST trial meetss primary endpoint in ovarian cancer

    GSK reports success in phase III trial of Zejula and Jemperli for advanced ovarian cancer, achieving significant progression-free survival improvement.
    GSK

    GSK Plc receives US FDA Breakthrough Therapy Designation

    GSK's Jemperli receives FDA Breakthrough Therapy Designation for treating locally advanced dMMR/MSI-H rectal cancer, expediting crucial development.
    Broker Ratings

    GSK plc 17.3% potential upside indicated by Berenberg Bank

    GSK

    GSK Plc Nucala COPD submission accepted by FDA

    GSK announces FDA review of Nucala for COPD treatment following successful MATINEE study data, aiming to be the first approved monthly biologic.
    GSK plc

    GSK plc RSV vaccine Arexvy approved in Japan

    GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage.

      Latest interviews

      View all interviews 

      Company Presentations

      View all Company Presentations

      Brokers Talk

      View all Broker Talk

      FTSE 100 News

      Search

      Search

      Green News

      View all Sustainable sectors, Plcs and news  

      Q&A's

      View all Question and Answers

      Funds

      View all Funds, Market Insights and news

      UK Broker Ratings

      Hardman & Co

      Don't Miss Our News Alerts

      Subscribe Free

      Find us on:

      Linkedin Facebook

      Useful links

      Disclaimer

      You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

      © 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.